PDCD1 and colorectal carcinoma: The group in Johns Hopkins University followed up with this clinical observation quickly with a phase 2 investigator-initiated study to further investigate the role of PD-1 blockade in treating patients with MSI-H and dMMR CRC or other tumors [4].